See more : Tianjin Jinbin Development Co., Ltd. (000897.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Ocugen, Inc. (OCGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocugen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RecycLiCo Battery Materials Inc. (AMY.V) Income Statement Analysis – Financial Results
- Hersha Hospitality Trust (HT-PE) Income Statement Analysis – Financial Results
- Anhui Province Natural Gas DevelopmentCo.,Ltd. (603689.SS) Income Statement Analysis – Financial Results
- Chularat Hospital Public Company Limited (CHG-R.BK) Income Statement Analysis – Financial Results
- Sports Ventures Acquisition Corp. (AKIC) Income Statement Analysis – Financial Results
Ocugen, Inc. (OCGN)
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.04M | 2.49M | 0.00 | 42.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 26.00K |
| Cost of Revenue | 704.00K | 1.07M | 589.00K | 6.35K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 1.42M | -589.00K | 36.27K | -60.61K | -49.62K | -1.53M | -1.67M | -1.61M | 0.00 | 8.00K | 26.00K |
| Gross Profit Ratio | 88.34% | 56.87% | 0.00% | 85.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 39.57M | 49.76M | 35.11M | 6.35M | 8.09M | 15.63M | 15.57M | 21.58M | 23.24M | 25.86M | 11.95M | 11.94M |
| General & Administrative | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Other Expenses | 0.00 | 3.52M | -310.00K | 182.66K | -784.87K | 1.43M | -116.00K | -248.00K | -72.00K | 13.00K | -52.00K | -30.00K |
| Operating Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Cost & Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Interest Income | 0.00 | 1.40M | 0.00 | 1.07K | 1.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 79.00K | 720.96K | 1.77M | 163.00K | 134.00K | -60.00K | -133.00K | -151.00K | 0.00 | 798.00K |
| Depreciation & Amortization | 704.00K | 480.00K | 589.00K | 102.11K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 726.00K | 566.00K | 638.00K |
| EBITDA | -64.83M | -88.59M | -58.03M | -21.00M | -18.41M | -14.42M | -24.88M | -11.38M | -30.28M | -21.92M | -16.22M | -14.33M |
| EBITDA Ratio | -1,074.01% | -3,411.09% | 0.00% | -33,085.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -91,800.00% | -50,734.62% |
| Operating Income | -65.53M | -84.87M | -58.03M | -21.28M | -14.16M | -30.11M | -24.95M | -30.31M | -31.82M | -32.66M | -16.85M | -14.97M |
| Operating Income Ratio | -1,085.67% | -3,411.09% | 0.00% | -49,940.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -210,562.50% | -57,569.23% |
| Total Other Income/Expenses | 2.45M | 2.27M | -389.00K | -536.95K | -6.08M | 11.89M | -1.46M | 14.10M | -205.00K | 9.87M | -8.87M | -1.97M |
| Income Before Tax | -63.08M | -81.35M | -58.42M | -21.82M | -20.24M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Income Before Tax Ratio | -1,045.03% | -3,269.73% | 0.00% | -51,201.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| Income Tax Expense | 0.00 | -4.00M | -52.00K | 801.52K | 982.96K | -15.76M | -186.00K | -15.82M | -1.17M | -10.52M | 8.88M | 1.94M |
| Net Income | -63.08M | -77.83M | -58.37M | -22.62M | -21.23M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Net Income Ratio | -1,045.03% | -3,128.38% | 0.00% | -53,081.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| EPS | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -68.21 | -145.22 | -891.47 | -120.93 | -79.65 |
| EPS Diluted | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -67.58 | -145.22 | -891.47 | -120.93 | -79.65 |
| Weighted Avg Shares Out | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.83K | 237.62K | 220.52K | 25.57K | 212.62K | 212.62K |
| Weighted Avg Shares Out (Dil) | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.84K | 239.82K | 220.52K | 25.57K | 212.62K | 212.62K |
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman,...
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Medicines Agency...
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary efficacy and safety...
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
Subsequent to quarter-end, closed $30 million in debt financing OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025 OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data...
Ocugen Secures $30 Million in Debt Funding
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024,...
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
MALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host an...
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety...
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a...
Source: https://incomestatements.info
Category: Stock Reports